PDCD1 and cancer: Overall, these studies demonstrated efficacy of anti-PD-1 in G/GEJ cancer, yet the inconsistent association between PD-L1 expression and benefit from anti-PD-1 indicates that efficacy is probably determined by further factors and that predictive biomarkers are urgently needed.